ViaDerma, Inc. (VDRM) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist ViaDerma, Inc. (VDRM) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 53/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026ViaDerma, Inc. (VDRM) Gesundheitswesen & Pipeline-Uebersicht
ViaDerma, Inc. is a specialty pharmaceutical company developing and marketing products like Vitastem, a topical antibiotic. Operating in the US, they license their technology in various therapeutic areas. With a high P/E ratio and focus on niche markets, ViaDerma seeks growth through product development and strategic partnerships in the competitive pharmaceutical landscape.
Investmentthese
ViaDerma, Inc. presents a high-risk, high-reward investment profile. The company's focus on specialty pharmaceutical products, particularly Vitastem, offers potential in niche markets. A high P/E ratio of 114.97 suggests market anticipation of future earnings growth, while a low Beta of 0.15 indicates lower volatility compared to the broader market. Growth catalysts include successful development and commercialization of pipeline products, as well as strategic licensing agreements. Key risks include reliance on a single product (Vitastem), competition from established pharmaceutical companies, and the challenges of navigating the regulatory landscape. The company's small market capitalization of $0.00B underscores its vulnerability to market fluctuations and operational setbacks.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- ViaDerma, Inc. operates as a specialty pharmaceutical company focusing on topical treatments.
- The company's lead product, Vitastem, is a tetracycline-based topical antibiotic used for various skin conditions.
- ViaDerma has a high P/E ratio of 114.97, suggesting potential growth expectations.
- The company boasts a gross margin of 100.0%, indicating efficient cost management in product sales.
- ViaDerma has a low Beta of 0.15, suggesting lower volatility compared to the market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Specialized product focus on topical treatments.
- Proprietary formulation of Vitastem.
- Potential for high gross margins (currently at 100%).
- Licensing opportunities for its technology.
Schwaechen
- Reliance on a single product (Vitastem) for revenue.
- Small market capitalization, making it vulnerable to market fluctuations.
- Limited financial resources for extensive R&D and marketing.
- OTC market listing, implying higher risk and lower liquidity.
Katalysatoren
- Upcoming: Potential FDA approval for new topical treatments in development.
- Ongoing: Expansion of Vitastem's market reach through strategic partnerships.
- Ongoing: Licensing agreements with other pharmaceutical companies.
- Upcoming: Positive clinical trial results for pipeline products.
- Upcoming: Potential acquisition or merger opportunities.
Risiken
- Potential: Competition from established pharmaceutical companies with greater resources.
- Potential: Regulatory hurdles and approval delays for new products.
- Ongoing: Reliance on a single product (Vitastem) for revenue.
- Potential: Patent expiration risks for Vitastem.
- Ongoing: OTC market listing implies higher risk and lower liquidity.
Wachstumschancen
- Expansion of Vitastem's Market Reach: ViaDerma has the opportunity to expand the market reach of Vitastem through strategic partnerships and targeted marketing campaigns. The global market for topical antibiotics is projected to reach billions of dollars by 2028, driven by increasing prevalence of skin infections and growing demand for effective treatments. By focusing on specific market segments, such as dermatology clinics and wound care centers, ViaDerma can increase Vitastem's sales and market share. Timeline: Ongoing.
- Development and Commercialization of New Products: ViaDerma's pipeline of products in development represents a significant growth opportunity. The company is targeting various therapeutic areas, including toenail fungal infections, diabetic amputations, and acne. Successful development and commercialization of these products would diversify ViaDerma's revenue streams and reduce its reliance on Vitastem. The market for these treatments is substantial, with the global market for antifungal drugs and acne treatments projected to reach billions of dollars in the coming years. Timeline: 2-5 years.
- Licensing Agreements and Technology Transfer: ViaDerma can leverage its technology and expertise through licensing agreements with other pharmaceutical companies. This would generate revenue and expand the reach of its products and technologies. The market for pharmaceutical licensing is robust, with numerous companies seeking to acquire or license innovative technologies and products. By actively pursuing licensing opportunities, ViaDerma can unlock significant value from its intellectual property. Timeline: Ongoing.
- Strategic Acquisitions and Partnerships: ViaDerma can pursue strategic acquisitions and partnerships to expand its product portfolio, market reach, and technological capabilities. This would accelerate its growth and enhance its competitive position. The pharmaceutical industry is characterized by frequent mergers and acquisitions, with companies seeking to consolidate their market positions and acquire new technologies. By identifying and pursuing strategic opportunities, ViaDerma can create significant value for its shareholders. Timeline: 1-3 years.
- Expansion into International Markets: ViaDerma has the opportunity to expand its operations into international markets. This would increase its sales and market share, and diversify its revenue streams. The global pharmaceutical market is vast, with significant growth opportunities in emerging markets. By carefully selecting target markets and developing appropriate market entry strategies, ViaDerma can successfully expand its international presence. Timeline: 3-5 years.
Chancen
- Expansion of Vitastem's market reach through partnerships.
- Development and commercialization of new products in its pipeline.
- Strategic acquisitions and partnerships to expand its portfolio.
- Expansion into international markets.
Risiken
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval processes.
- Patent expiration risks for Vitastem.
- Potential for product liability claims.
Wettbewerbsvorteile
- Proprietary formulations, particularly for Vitastem.
- Licensing agreements that generate recurring revenue.
- Focus on niche markets with less competition from major pharmaceutical companies.
Ueber VDRM
ViaDerma, Inc., established in 2007 and headquartered in Marina Del Rey, California, operates as a specialty pharmaceutical company in the United States. Originally named Décor Products International, Inc., the company rebranded to ViaDerma, Inc. in May 2014, signaling a strategic shift towards the pharmaceutical sector. The company focuses on the development, marketing, and licensing of pharmaceutical products, targeting various therapeutic areas. ViaDerma's flagship product, Vitastem, is a tetracycline-based topical antibiotic designed for treating cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond Vitastem, ViaDerma is actively engaged in developing a pipeline of products addressing conditions such as toenail fungal infections, diabetic amputations, acne, psoriasis, eczema, burns, anti-aging solutions, medical cannabis applications, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company's business model involves both direct marketing of its products and licensing its technology to other pharmaceutical companies, aiming to broaden its market reach and revenue streams.
Was das Unternehmen tut
- Develops and markets pharmaceutical products.
- Licenses its technology to other pharmaceutical companies.
- Focuses on specialty pharmaceutical products.
- Markets Vitastem, a tetracycline-based topical antibiotic.
- Develops products for various therapeutic areas, including dermatology and wound care.
- Aims to address conditions such as acne, psoriasis, and eczema.
Geschaeftsmodell
- Develops and markets its own pharmaceutical products, such as Vitastem.
- Licenses its pharmaceutical technology to other companies for revenue.
- Focuses on niche markets within the pharmaceutical industry.
Branchenkontext
ViaDerma, Inc. operates within the specialty pharmaceutical industry, a segment characterized by its focus on niche markets and specialized treatments. The industry is driven by innovation, regulatory approvals, and market demand for targeted therapies. Competition is intense, with both large pharmaceutical companies and smaller, specialized players vying for market share. The global pharmaceutical market is projected to reach trillions of dollars by 2026, with specialty drugs representing a significant growth area. ViaDerma's success depends on its ability to develop and commercialize innovative products, secure regulatory approvals, and effectively compete in this dynamic landscape.
Wichtige Kunden
- Individuals seeking treatment for cuts, scrapes, wounds, infections, burns, acne, psoriasis, and eczema.
- Pharmaceutical companies licensing ViaDerma's technology.
- Healthcare providers recommending or prescribing ViaDerma's products.
Finanzdaten
Chart & Info
ViaDerma, Inc. (VDRM) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Friday
· 4. Okt. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer VDRM.
Kursziele
Wall-Street-Kurszielanalyse fuer VDRM.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von VDRM auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Christopher A Otiko
CEO
Christopher A. Otiko serves as the CEO of ViaDerma, Inc. His background includes experience in business development and management within the pharmaceutical and healthcare sectors. Otiko has been involved in strategic planning, product development, and marketing initiatives. His expertise lies in identifying market opportunities and driving growth for specialty pharmaceutical companies. He is responsible for overseeing ViaDerma's operations and executing its strategic vision.
Erfolgsbilanz: Under Christopher A. Otiko's leadership, ViaDerma has focused on developing and marketing Vitastem, a key product for the company. He has overseen the company's efforts to expand its product pipeline and pursue licensing agreements. Key milestones include the rebranding of the company to ViaDerma, Inc. and the continued development of new topical treatments.
VDRM OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that ViaDerma, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volumes can lead to price manipulation.
- Higher bid-ask spreads increase transaction costs.
- OTC stocks are more susceptible to fraud and scams.
- Delisting risk is higher due to less stringent requirements.
- Verify the company's registration with the SEC.
- Review available financial statements, if any.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Understand the company's business model and revenue streams.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Company has a registered business address.
- Company has a functioning website.
- Company has a listed phone number.
- Company has a CEO and management team.
- Company has a product (Vitastem) being marketed.
ViaDerma, Inc. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for VDRM?
ViaDerma, Inc. (VDRM) currently holds an AI score of 53/100, indicating moderate score. Key strength: Specialized product focus on topical treatments.. Primary risk to monitor: Potential: Competition from established pharmaceutical companies with greater resources.. This is not financial advice.
How frequently does VDRM data refresh on this page?
VDRM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven VDRM's recent stock price performance?
Recent price movement in ViaDerma, Inc. (VDRM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product focus on topical treatments.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider VDRM overvalued or undervalued right now?
Determining whether ViaDerma, Inc. (VDRM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying VDRM?
Before investing in ViaDerma, Inc. (VDRM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VDRM to a portfolio?
Potential reasons to consider ViaDerma, Inc. (VDRM) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialized product focus on topical treatments.. Additionally: Proprietary formulation of Vitastem.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of VDRM?
Yes, most major brokerages offer fractional shares of ViaDerma, Inc. (VDRM) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track VDRM's earnings and financial reports?
ViaDerma, Inc. (VDRM) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for VDRM earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be limited due to the company's OTC listing.
- Financial data may not be fully comprehensive or up-to-date.